DYAI News & Events

Dyadic International announced that Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome. The company said, "A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance of pandemic preparedness and highlighted the need to improve the speed, scalability, flexibility, and cost-effectiveness of biologic manufacturing during rapidly evolving public health events. The collaboration builds upon Dyadic's prior Andes virus monoclonal antibody work and combines the complementary expertise of Dyadic and Scripps Research to further assess the potential of Dyadic's proprietary C1 platform for rapid development timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious disease preparedness."

Dyadic Applied BioSolutions entered into an original equipment manufacturer distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales channels, expanding market access and supporting Dyadic's objective of generating ongoing, product-based revenues. The initial products expected to be offered under the agreement include recombinant DNase I and recombinant transferrin, with a focus on research-use-only applications. Dyadic expects to offer both human and bovine transferrin, along with additional cell culture-relevant recombinant proteins, as part of a broader and expanding product portfolio.

Dyadic Applied BioSolutions and Fermbox Bio announced the commercial launch of animal-origin-free Recombinant DNase I. This represents the first commercialized product under the companies expanded collaboration announced in 2025 and marks another step in Dyadic's accelerating transition from platform development to commercial product expansion and recurring revenue growth. Produced using Dyadic's proprietary high-yield fungal microbial expression platforms and Fermbox Bio's scale-up and biomanufacturing capabilities, Recombinant DNase I is currently available in research grade with a cGMP-grade version in development to support biopharmaceutical manufacturing and cell and gene therapy applications. Recombinant DNase I is an endonuclease enzyme used for nucleic-acid clean-up and sample preparation workflows where residual DNA can interfere with analytical results. Its RNase-free specification supports RNA integrity in sensitive RNA workflows across biological research, biotechnology, and molecular diagnostics. DNase I is a strategically important enzyme and the first in a planned series of recombinant enzymes and proteins expected to be commercially introduced throughout 2026.